AXIN2 and hepatoblastoma: Meanwhile epigenetic and genetic impairment mutations that reduce expression of wild-type AXIN2/CONDUCTIN [13],[14] or amino-terminal missense mutations in CTNNB1 (β-CATENIN) [15] are most commonly associated with aberrant WNT signaling in cancers of the liver (hepatocellular carcinoma and hepatoblastoma), stomach, kidney (Wilms tumor) and ovaries.